Terms: = Breast cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Prognosis
12 results:
1. cdk12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract] [Full Text] [Related]
2. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
3. ERBB2-amplified lobular breast carcinoma exhibits concomitant cdk12 co-amplification associated with poor prognostic features.
Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
[TBL] [Abstract] [Full Text] [Related]
4. Genetic and clinical landscape of ER + /PR- breast cancer in China.
Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of a novel dual-target inhibitor of cdk12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
[TBL] [Abstract] [Full Text] [Related]
6. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
[TBL] [Abstract] [Full Text] [Related]
7. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
8. cdk12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract] [Full Text] [Related]
9. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
10. Low expression of cdk12 in gastric cancer is correlated with advanced stage and poor outcome.
Liu M; Fan H; Li T; Sihong L; Qiao S; Bi J
Pathol Res Pract; 2020 Jul; 216(7):152962. PubMed ID: 32534699
[TBL] [Abstract] [Full Text] [Related]
11. cdk12 Promotes breast cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling.
Peng F; Yang C; Kong Y; Huang X; Chen Y; Zhou Y; Xie X; Liu P
Curr Cancer Drug Targets; 2020; 20(2):156-165. PubMed ID: 31744448
[TBL] [Abstract] [Full Text] [Related]
12. Genome profiling of ERBB2-amplified breast cancers.
Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
[TBL] [Abstract] [Full Text] [Related]